Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma

• Status: Unknown status
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Treatment of locally advanced and metastatic squamous cell carcinoma of the lung involves the use of chemotherapy as the therapeutic mainstay. Platinum-etoposide regimens (such as cisplatin-etoposide) are the most commonly used chemotherapeutic regimen, which is delivered intravenously in the standard three-weekly intervals.

Recent interest in oral metronomic chemotherapy has arisen, especially due to its beneficial effects in delaying disease progression among heavily pre-treated patients with various malignancies.

This study attempts to combine the use of metronomic chemotherapy concurrently during standard intravenous chemotherapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Swami Rama Cancer Hospital and Research Institute
• Treatments: Cisplatin; Cyclophosphamide; Etoposide; Etoposide phosphate

Criteria

Inclusion Criteria:

• Histopathologically proven squamous cell carcinoma of the lung

• Surgically unresectable or metastatic disease

Exclusion Criteria:

• Severe life limiting diabetes, hypertension or cardiac co-morbidities

• Co-existing tuberculosis

• Brain metastases at presentation

• Non-consenting patients

• Previously treated with any regimen of chemotherapy for existing or previous malignancy